BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets trimmed its position in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) by 83.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 44,381 shares of the company’s stock after selling 228,754 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.11% of BioXcel Therapeutics worth $27,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in BTAI. XTX Topco Ltd raised its position in shares of BioXcel Therapeutics by 49.0% during the 2nd quarter. XTX Topco Ltd now owns 46,503 shares of the company’s stock worth $60,000 after purchasing an additional 15,291 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in BioXcel Therapeutics during the 2nd quarter worth $39,000. Finally, Armistice Capital LLC increased its position in BioXcel Therapeutics by 705.2% in the second quarter. Armistice Capital LLC now owns 2,987,000 shares of the company’s stock worth $3,823,000 after buying an additional 2,616,027 shares during the period. 30.68% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on BTAI. HC Wainwright reduced their price target on shares of BioXcel Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a report on Monday, October 21st. Canaccord Genuity Group restated a “buy” rating and issued a $7.00 price target on shares of BioXcel Therapeutics in a research note on Friday, August 30th.

BioXcel Therapeutics Stock Performance

NASDAQ:BTAI opened at $0.34 on Friday. The stock has a market cap of $14.58 million, a price-to-earnings ratio of -0.16 and a beta of 0.11. BioXcel Therapeutics, Inc. has a 1 year low of $0.30 and a 1 year high of $4.17. The business has a fifty day moving average of $0.54 and a 200-day moving average of $0.79.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.